Keenova Therapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Keenova Therapeutics Plc (MNK) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Keenova Therapeutics Plc vs Its Competitors
- TTM: Trailing 12-month revenue of 1,413M vs 254,479M combined for its competitors (0.6% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+32.4% annualized vs trailing 12 months), vs decelerating (-8.0%) for its tracked peer group.
- Growth: Keenova Therapeutics Plc generated 11.4% revenue growth year over year in Q1 2026, vs 8.7% for its competitors combined.
- Profitability: Its -24.3% net margin compares with 9.5% for the peer group.
- Peer revenue share: Keenova Therapeutics Plc accounted for 0.8% of combined revenue among its tracked peer group, up from 0.8% a year earlier.
- Peer differentiation: Revenue per employee of $0.88M compares with $0.99M for the peer group (0.9x).
- Structure: Keenova Therapeutics Plc reports the following subsidiaries: Endo LP.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
MNK Sales vs. its Competitors, Q1 2026
Keenova Therapeutics Plc reported revenue growth of 11.36 % year on year in Q1 2026, above its competitors' combined revenue growth of 8.69 %.
With a net margin of -24.27 %, Keenova Therapeutics Plc reported lower profitability than its competitors (9.51 %).
Keenova Therapeutics Plc generated 0.79 % of the combined sales of its peer group, up from 0.77 % a year earlier.
API endpoints for this dataset
Keenova Therapeutics Plc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Keenova Therapeutics Plc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Keenova Therapeutics Plc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Keenova Therapeutics Plc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Keenova Therapeutics Plc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 8.9% year over year, combined, vs 11.4% for Keenova Therapeutics Plc. Keenova Therapeutics Plc's share of combined industry revenue moved from 0.09% to 0.09%, a gain of 0.00 percentage points.
Keenova Therapeutics Plc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Keenova Therapeutics Plc | No | No | No | No |
| Competitors combined (51) | ||||
| High-Confidence Competitors (5) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 0.00 % (0 of 8) | 62.50 % (5 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
MNK Stock Performance relative to its Competitors
MNK Stock Performance relative to High-Confidence Competitors
MNK Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Eton Pharmaceuticals Inc | 282.9% | Outperformed |
| 2 | Avadel Pharmaceuticals Plc | 282.9% | Outperformed |
| 3 | Evoke Pharma Inc | 282.9% | Outperformed |
| 4 | Ironwood Pharmaceuticals inc | 282.9% | Outperformed |
| 5 | Kalvista Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Keenova Therapeutics Plc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Keenova Therapeutics Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Keenova Therapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Keenova Therapeutics Plc |
13.47 | 1,413.00 |
 Abbvie Inc |
516,201.32 | 66,014.00 |
 Amgen Inc |
250,468.48 | 38,095.00 |
 Pfizer Inc |
169,021.89 | 63,625.00 |
 Vertex Pharmaceuticals Inc |
139,617.37 | 12,951.60 |
 Regeneron Pharmaceuticals Inc |
95,499.36 | 16,896.20 |
| SUBTOTAL | 1,303,068.85 | 274,260.97 |
Sign in to see all competitors of Keenova Therapeutics Plc.
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Keenova Therapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Keenova Therapeutics Plc's Competitors Named by the Company
Competitive relationships identified from Keenova Therapeutics Plc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Ovid Therapeutics Inc | Company report | 85% |
| Nu med Plus Inc | Company report | 85% |
| Trevena inc | Company report | 85% |
| ANI Pharmaceuticals Inc. | Company report | 85% |
| Jaguar Health Inc | Company report | 85% |
| Beyond Air Inc | Company report | 85% |
| Lannett Company Inc | Company report | 85% |
| Teva Pharmaceutical Industries Limited | Company report | 85% |
| Bausch Health Companies Inc | Company report | 85% |
| Endo International Plc | Company report | 85% |
| Collegium Pharmaceutical Inc | Company report | 85% |
| Amneal Pharmaceuticals Inc | Company report | 85% |
| Eton Pharmaceuticals Inc | Company report | 85% |
| Eagle Pharmaceuticals inc | Company report | 85% |
| Perrigo Company Plc | Company report | 85% |
| Indivior Pharmaceuticals Inc | Company report | 85% |
| Abbvie Inc | Company report | 85% |
| Viatris Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Keenova Therapeutics Plc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Keenova Therapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Amgen Inc | Reportable 100.00 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Teva Pharmaceutical Industries Limited | United States 42.55 % |
| Viatris Inc | Developed Markets 59.34 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Keenova Therapeutics Plc | 13 | 883,125 | -358,188 |
| Abbvie Inc | 516,201 | 1,158,140 | 181,509 |
| Amgen Inc | 250,468 | 2,930,385 | 672,538 |
| Pfizer Inc | 169,022 | 848,333 | 54,160 |
| Vertex Pharmaceuticals Inc | 139,617 | 31,979,259 | 9,817,037 |
| Regeneron Pharmaceuticals Inc | 95,499 | 1,096,444 | 312,615 |
| PEERS TOTAL | 1,303,055 | 987,456 | 93,110 |
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Pfizer Inc | United States 63.93 % |
| Vertex Pharmaceuticals Inc | United States 63.04 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Perrigo Company Plc | United States 62.82 % |
| Amphastar Pharmaceuticals Inc | US 91.94 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (444 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 42.29 % | 37.99 % (avg) | +4.3 pp |
| Operating Margin | -35.61 % | industry median | -36.7 pp |
| EBITDA Margin | -12.14 % | -6.20 % (avg) | -5.9 pp |
| Capital Intensity (Capex / Revenue) | - | 7.59 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Keenova Therapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | -4.71 % | -0.19 % | -1.65 % | -30.01 % | -0.21 % | - | 0.00 % | -36.69 % |
| Operating Margin | 13.04 % | -115.71 % | -57.62 % | -29.44 % | -9.19 % | -9.19 % | -9.19 % | -27.56 % |
| Return on Invested Capital | 2.22 % | -20.07 % | -15.99 % | -9.94 % | -2.63 % | -2.79 % | -4.04 % | -5.35 % |
| P/E | 1.0x | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Keenova Therapeutics Plc's Strategic Group Map
Keenova Therapeutics Plc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
Keenova Therapeutics Plc's trailing-12-month revenue growth of -38.6% and operating margin of -35.6% compares with an average of -23.7% growth and -17.3% margin across its 8 closest peers by combined growth, margin and ROIC -- Keenova Therapeutics Plc sits below that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Keenova Therapeutics Plc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Keenova Therapeutics Plc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Keenova Therapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+32.4% annualized vs trailing 12 months).
Weaknesses
- Operating margin 36.7 points below the industry median.
- Return on equity 42.9 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of competitors (34.70 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-8.0% annualized).
Methodology: see Methodology: SWOT Analysis.
Keenova Therapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Keenova Therapeutics Plc | 1.07 | 3.15 | 1.11 |
| Abbvie Inc | 0.19 | 0.79 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Vertex Pharmaceuticals Inc | 1.30 | 2.83 | 0.06 |
| Regeneron Pharmaceuticals Inc | 0.58 | 3.56 | 0.06 |
Sign in to see all peers for Keenova Therapeutics Plc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Keenova Therapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Keenova Therapeutics Plc | Q1 2026 | -7.4 % | - |
| Abbvie Inc | Q3 2026 | +10.3 % | +2,143.6 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +11.8 % | -39.6 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +36.3 % | +33.5 % |
| PEERS TOTAL | -0.1 % | - |
Sign in to see all peers for Keenova Therapeutics Plc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Keenova Therapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Keenova Therapeutics Plc | Q1 2026 | -1.1 % | -49.5 % |
| Abbvie Inc | Q3 2026 | -19.2 % | -21.0 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Vertex Pharmaceuticals Inc | Q3 2026 | +26.8 % | -4.4 % |
| Regeneron Pharmaceuticals Inc | Q3 2026 | +104.1 % | +49.1 % |
Sign in to see all peers for Keenova Therapeutics Plc.
Keenova Therapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Keenova Therapeutics Plc | - | - | - |
| Abbvie Inc | 7.48% | 12.87% | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Vertex Pharmaceuticals Inc | 14.16% | 16.63% | 20.08% |
| Regeneron Pharmaceuticals Inc | 11.50% | 13.00% | 15.07% |
Sign in to see all peers for Keenova Therapeutics Plc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Keenova Therapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Keenova Therapeutics Plc | - | 0.01 |
| Abbvie Inc | 50.14 | 7.82 |
| Amgen Inc | 28.60 | 6.57 |
| Pfizer Inc | 41.83 | 2.66 |
| Vertex Pharmaceuticals Inc | 35.27 | 10.78 |
| Regeneron Pharmaceuticals Inc | 20.00 | 5.65 |
| PEERS AVERAGE | 51.80 | 4.75 |
Sign in to see all peers for Keenova Therapeutics Plc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.